| |
|
|
|
|
|
| |
|
|
|
 |
| |
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
 |
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
Composition |
| |
|
|
|
|
| |
|
|
|
Each metered dose canister of DUOFLAM Spray contains: |
| |
|
|
|
Diclofenac Diethylamine … 1.16% w/w
Menthol … 5% w/w
Methyl Salicylate … 10% w/w
Benzyl alcohol … 1% w/v
Linseed oil (Oleum Lini) … 3% w/w
Excipients & propellant … q.s. to 100% w/w |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
Therapeutic Indications & Usage |
| |
|
|
|
|
| |
|
|
|
DUOFLAM Spray is indicated for temporary relief of arthritis pain, sprain, tendinitis, fasciitis,epicondylitis, rotator cuff lesions, as well as muscle soreness as in strain, myalgia and backache.
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
Contraindications |
| |
|
|
|
|
| |
|
|
|
DUOFLAM Spray is not advocated on those with known hypersensitivity to its ingredients.
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
Precautions & Warnings |
| |
|
|
|
|
| |
|
|
|
DUOFLAM Spray is for external use only. If skin irritation develops following its use, if pain persists lasts
for 7 days or more, or if redness develops, discontinue DUOFLAM, and physician consultation must be
immediately sought. Heating pad is not to be used after application of DUOFLAM Spray.
|
| |
|
|
|
|
| |
|
|
|
In those who have had an adverse reaction to oral NSAID, such as asthma, gastric erosion or exacerbation of renal impairment, DUOFLAM Spray should preferably be avoided.
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
| Adverse Reactions |
|
| |
|
DUOFLAM Spray ingredients can cause rarely local skin reactions
such as allergic rash and erythema; systemic side effects are
even rarer (< 0.5%). Local or systemic adverse reactions
necessitating drug stoppage of DUOFLAM Spray application are likely to be uncommon (0.5%).
|
| Recommended Dosage & Administration |
| |
1-2 DUOFLAM Sprays on the affected area upto three times daily,
or as prescribed.
|
| |
| Presentations |
| |
| DUOFLAM Spray: Single pack with metered dose 20 gm canister. |
| |
| |
| |
| |
| |
| |
|
 |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
